Surgical Care

Category: Cancer (Oncology), Surgery, HIC#12472
Title:
Phase I Study of Induction Therapy with VELCADE and Vorinostat in Patients with Surgically Resectable Non-small Cell Lung Cancer
Contact:Sandra Burks
Phone:(434)243-0315
E-mail:sgb2c@virginia.edu

UVa Health System Department of Surgery seeks adults with lung cancer who are being scheduled for surgery to remove the cancer for Phase I research study.

The purpose of this study is to find out what effects (both good and bad) two medications (VELCADE and Vorinostat) have on patients who have certain types of lung cancer. The study is dose escalating meaning that patients will receive different doses of medication depending on when they enter the study. Participation in the study will last approximately 3 months and will include an initial screening visit, a visit once each week for 3 weeks to receive the study medications, and then 2 additional visits around the time of your surgery to remove your lung cancer tumor.

The costs of the study medications are paid for by the research, and there are no additional costs expected for patients participating in this trial. There is no financial compensation for patients who participate.

Contact Information:

For more information please contact:
Study coordinators in the Surgical Therapeutic Advancement Center
Office: 434-243-0315
Email: uvastac@virginia.edu

IRB # 12472
Principal Investigator: David Jones, MD
Primary Investigator: Jones David, R
Department: Surgery
Division: Thoracic & Cardiovascular Surgery 		Accepts adult enrollment :YES
Accepts minor enrollment :NO